Baseline patient demographic and disease characteristics
| Characteristic . | IM + DAS resistant (n = 37) . | IM + DAS intolerant (n = 50) . | IM + NI resistant (n = 27) . | IM + DAS ± NI (n = 4)* . | Total (n = 118) . |
|---|---|---|---|---|---|
| Median age, y (range) | 54.0 (23-69) | 58.0 (25-79) | 52.0 (20-73) | 54.5 (31-62) | 56.0 (20-79) |
| Sex, n (%) | |||||
| Female | 23 (62) | 27 (54) | 13 (48) | 2 (50) | 65 (55) |
| Male | 14 (38) | 23 (46) | 14 (52) | 2 (50) | 53 (45) |
| Race, n (%) | |||||
| White | 27 (73) | 38 (76) | 17 (63) | 3 (75) | 85 (72) |
| Asian | 4 (11) | 9 (18) | 3 (11) | 0 | 16 (14) |
| Other | 6 (16) | 3 (6) | 7 (26) | 1 (25) | 17 (14) |
| Median duration of CML disease, y (range) | 7.5 (1.2-17.6) | 5.6 (0.6-18.3) | 5.9 (1.2-16.3) | 11.7 (2.2-11.9) | 6.7 (0.6-18.3) |
| ECOG Performance Status, n (%)† | |||||
| 0 | 28 (76) | 31 (62) | 25 (93) | 2 (50) | 86 (74) |
| 1 | 9 (24) | 18 (36) | 2 (7) | 2 (50) | 31 (26) |
| Median duration of prior therapy, (range) | |||||
| Imatinib, y | 2.6 (0.02-6.4) | 3.3 (0.1-6.6) | 2.5 (0.7-5.9) | 3.0 (1.4-6.4) | 2.7 (0.02-6.6) |
| Dasatinib, mo | 18.3 (1.7-47.9) | 17.3 (1.1-35.7) | 0 | 4.1 (1.3-6.9) | 17.7 (1.1-47.9) |
| Nilotinib, mo | 0 | 0 | 12.7 (1.7-38.9) | 5.4 (0.8-6.1) | 9.2 (0.8-38.9) |
| Additional prior therapies, n (%) | |||||
| Interferon | 25 (68) | 24 (48) | 10 (37) | 2 (50) | 61 (52) |
| Stem cell transplant | 2 (5) | 5 (10) | 0 | 2 (50) | 9 (8) |
| Characteristic . | IM + DAS resistant (n = 37) . | IM + DAS intolerant (n = 50) . | IM + NI resistant (n = 27) . | IM + DAS ± NI (n = 4)* . | Total (n = 118) . |
|---|---|---|---|---|---|
| Median age, y (range) | 54.0 (23-69) | 58.0 (25-79) | 52.0 (20-73) | 54.5 (31-62) | 56.0 (20-79) |
| Sex, n (%) | |||||
| Female | 23 (62) | 27 (54) | 13 (48) | 2 (50) | 65 (55) |
| Male | 14 (38) | 23 (46) | 14 (52) | 2 (50) | 53 (45) |
| Race, n (%) | |||||
| White | 27 (73) | 38 (76) | 17 (63) | 3 (75) | 85 (72) |
| Asian | 4 (11) | 9 (18) | 3 (11) | 0 | 16 (14) |
| Other | 6 (16) | 3 (6) | 7 (26) | 1 (25) | 17 (14) |
| Median duration of CML disease, y (range) | 7.5 (1.2-17.6) | 5.6 (0.6-18.3) | 5.9 (1.2-16.3) | 11.7 (2.2-11.9) | 6.7 (0.6-18.3) |
| ECOG Performance Status, n (%)† | |||||
| 0 | 28 (76) | 31 (62) | 25 (93) | 2 (50) | 86 (74) |
| 1 | 9 (24) | 18 (36) | 2 (7) | 2 (50) | 31 (26) |
| Median duration of prior therapy, (range) | |||||
| Imatinib, y | 2.6 (0.02-6.4) | 3.3 (0.1-6.6) | 2.5 (0.7-5.9) | 3.0 (1.4-6.4) | 2.7 (0.02-6.6) |
| Dasatinib, mo | 18.3 (1.7-47.9) | 17.3 (1.1-35.7) | 0 | 4.1 (1.3-6.9) | 17.7 (1.1-47.9) |
| Nilotinib, mo | 0 | 0 | 12.7 (1.7-38.9) | 5.4 (0.8-6.1) | 9.2 (0.8-38.9) |
| Additional prior therapies, n (%) | |||||
| Interferon | 25 (68) | 24 (48) | 10 (37) | 2 (50) | 61 (52) |
| Stem cell transplant | 2 (5) | 5 (10) | 0 | 2 (50) | 9 (8) |